RESONATE™: OS in monotherapy for previously treated CLL/SLL1

Secondary endpoint: OS with IMBRUVICA® vs ofatumumab1,2
 

Primary analysis: IMBRUVICA® achieved a 57% statistically significant reduction in the risk of death1,2